ArticleScientific reports2026
Plasma COL3A1 propeptide as a promising prognostic marker in oral squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we aimed to evaluate the prognostic significance of collagens in patients with oral squamous cell carcinoma (OSCC). Plasma proteomics data from 40 OSCC patients and 33 healthy controls, generated using the Olink Explore 3072 platform, along with microarray gene expression data from 29 OSCC tumours, 21 clinically normal tissues contralateral to tumour (NTCT), and 14 healthy controls, were analysed to assess expression levels of collagens and their associations with clinicopathological variables and survival outcomes. Eleven collagen peptides were detected in plasma. Higher circulating levels of collagen type III alpha 1 chain (COL3A1) propeptides were associated with improved overall survival and longer disease-free time (p < 0.05). Penalised Cox regression using the least absolute shrinkage and selection operator (LASSO) supported COL3A1 propeptide as a survival-associated feature. Comparison of protein profiles between COL3A1-low and COL3A1-high patients identified neutrophil degranulation as the most significantly enriched pathway. Microarray differential expression analysis showed COL3A1 mRNA to be significantly upregulated in tumour tissues compared with NTCT and healthy controls (FDR < 0.05). Circulating COL3A1 propeptide shows potential as a prognostic biomarker for OSCC and may reflect systemic immune-related alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.